The FDA has granted Fast Track designation to pevifoscorvir sodium, an oral capsid assembly modulator for chronic HBV.

Dyno Therapeutics, Inc., a genetic technologies company applying artificial intelligence (AI) to solve the grand challenge of in vivo gene delivery, today announced that Astellas Pharma Inc. (TSE: ...

Establishing an innovative class of polyomavirus antivirals spanning BK and JC virus indications CANTON, Mass.--(BUSINESS ...

A collaborative research team led by Kazuyoshi Murata determined the capsid structure of the giant Melbournevirus at 4.4 Å resolution using cryo-electron microscopy. By applying a block-based ...

Health Canada cleared expansion of UPBEAT into Canadian sites for adults with genetically confirmed BAG3 DCM, a high-mortality inherited cardiomyopathy lacking mechanism-targeted therapy. Proprietary ...

Aligos remains eligible for up to $420m in milestones and tiered, high single-digit royalties on Amoytop’s net sales.

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high ...

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size ...

Len is a gamechanging drug to prevent HIV infections, priced by Gilead at $28,200. Limited drug is available at cost to ...

Researchers at the Manchester Institute of Biotechnology (MIB) have used engineering biology—an emerging technology that uses ...

Aligos Therapeutics has secured a $25 million cash infusion in return for selling the China rights to its phase 2-stage ...